You only have to look at the other two ASX biotech's CB is...

You only have to look at the other two ASX biotech's CB is involved in to see his MO and how thorough and professional he is in his approach to everything he does. Let alone the credentials of Ros and the rest of the Executive/Advisory Board.

Every Investor Update in the past year or so has specifically mentioned on-going partnership discussions, with successful readout a major catalyst/inflection point to accelerate these discussions. The most recent Bioshares presso went into considerable detail about global M&A activity in this space, and how FTT is positioned to benefit following successful readout.

Yesterday there were only 50,000 shares left on the bid to test the gap at 4.3. At one point in the morning 4.3 was the top bid. The SP didn't get there. Buyers came in over the top and filled the gap at 4.4 before moving up. Big green candle to close the day on the high.

Today we are back at 4.8-4.9 with approx 900K shares on the bid down to 4.4 with another 288K @ 4.3. - at time of writing.

Meanwhile, Twiggs Money Flow continues to show bullish divergence to accumulation in the face of SP retrace over the past few weeks

Seems pretty clear to me what's happening.

Assuming successful readout - and all commentary thus far suggest this to be odds-on, the only way I see this as a binary outcome is vis-a-vis whether it's a pure exit play, or a partnership play to fund EU dossier and begin Ph3 in the US. Bearing in mind the slide about having to kill us if they told us about "Our Deal?"

The spec end of things isn't exactly a raging bull at the moment.​

I'd suggest any SP weakness and/or perceived market apathy is more to do with legacy issues from TIS than the science and the Ph2b, or FTT not engaging in market PR.

Once bitten twice shy for many retail punters.

To me that spells opportunity, but that's just me.